Latest news

Debiopharm International SA and the Paul Scherrer Institute announce a licensing agreement for the development of a novel targeted radiotherapeutic…

The Japanese Cancer Association and Debiopharm Group Announce Winners of the 2018 JCA-Mauvernay Award

Le Challenge Debiopharm-Inartis récompense ses cinq finalistes 2018

Debiopharm Investment, BNP Paribas Développement, Bpifrance et Tikehau Capital accompagnent la croissance du groupe Carbonex

FDA Grants Fast Track designation to Debiopharm International’s Debio 1347 for the treatment of patients with unresectable or metastatic tumors…

Kaiku Health raises €4.4 million series A financing to accelerate its digital therapeutics pipeline led by Debiopharm and Tesi

Challenge Qualité de vie du patient 2018 : l’appel à projets est ouvert !

GenePOC launches its revogene™ instrument and GBS LB test in Canada

Debiopharm continues the fight against antibiotic resistance with investment in ABAC Therapeutics Inc.